Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting (Q40262046)

19 September 2017

Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting (English)

1 reference

19 September 2017

1 reference

1 reference

Maria L Jaramillo

1

1 reference

19 September 2017

Zully Leon

2

1 reference

19 September 2017

Suzanne Grothe

3

1 reference

19 September 2017

Beatrice Paul-Roc

4

1 reference

19 September 2017

Abedelnasser Abulrob

5

1 reference

19 September 2017

Maureen O'Connor McCourt

6

1 reference

19 September 2017

language of work or name

English

0 references

publication date

23 May 2006

1 reference

Experimental Cell Research

19 September 2017

1 reference

19 September 2017

312

1 reference

19 September 2017

2778-2790

1 reference

19 September 2017

15

1 reference

Trafficking of the ErbB receptors and its influence on signaling

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Endocytosis and signaling. an inseparable partnership

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Signaling on the endocytic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Human mammary epithelial cells rapidly exchange empty EGFR between surface and intracellular pools

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Endocytosis and lysosomal targeting of epidermal growth factor receptors are mediated by distinct sequences independent of the tyrosine kinase domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Recruitment of epidermal growth factor receptors into coated pits requires their activated tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Lysosomal targeting of epidermal growth factor receptors via a kinase-dependent pathway is mediated by the receptor carboxyl-terminal residues 1022-1123.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Aspects of the metabolism of the epidermal growth factor receptor in A431 human epidermoid carcinoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Ligand-induced endocytosis of the EGF receptor is blocked by mutational inactivation and by microinjection of anti-phosphotyrosine antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

A monoclonal antibody to the human epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Modulation of transforming growth factor alpha-dependent expression of epidermal growth factor receptor gene by transforming growth factor beta, triiodothyronine, and retinoic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Effect of tyrosine kinase inhibitors on clathrin-coated pit recruitment and internalization of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Epidermal growth factor receptor: mechanisms of activation and signalling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Novel mechanism for regulation of epidermal growth factor receptor endocytosis revealed by protein kinase A inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Clathrin-independent endocytosis of ubiquitinated cargos

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

The EGF receptor: a nexus for trafficking and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Second cysteine-rich region of epidermal growth factor receptor contains targeting information for caveolae/rafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Interactions of EGFR and caveolin-1 in human glioblastoma cells: evidence that tyrosine phosphorylation regulates EGFR association with caveolae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Regulated migration of epidermal growth factor receptor from caveolae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Assessment of epidermal growth factor receptor with 99mTc-ethylenedicysteine-C225 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Protein toxins: intracellular trafficking for targeted therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2006.05.008

10.1016/J.YEXCR.2006.05.008

7 January 2021

Identifiers

DOI

1 reference

19 September 2017

1 reference